Dr. Kuo on PSMA-PET imaging biomarker research
June 21st 2022Phillip Kuo, MD, PhD, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.
Dr. Nicole Miller discusses her BPH practice
June 20th 2022“I think that there's certainly recognition that HoLEP is a procedure that can be self-taught and learned. But I think the learning curve is significantly shortened if you're mentored and certainly if you're fellowship trained,” says Nicole L. Miller, MD, FACS.
FDA clears hyaluronic acid rectal spacer for use during prostate radiotherapy
June 15th 2022Barrigel, which is made from Non-Animal Stabilized Hyaluronic Acid (NASHA), is used to separate and increase the distance between the anterior rectal wall and the prostate when the patient is receiving radiotherapy.
Dr. Lotan on the iodine-based contrast media shortage
June 13th 2022“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.
Investigators assess the quality of UTI information from top-grossing YouTube videos
June 7th 2022“Less than half of the videos actually featured a medical provider, so a majority of videos are being produced by non-medical providers, commercial media, or individual YouTubers with no medical experience,” says Connie Huang, MD.
Dr. Armstrong on recent ARCHES data in metastatic hormone-sensitive prostate cancer
June 6th 2022“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.
Dr. Choueiri highlights new adjuvant pembrolizumab findings in high-risk renal cell carcinoma
June 3rd 2022The new findings, “further support the use of adjuvant pembrolizumab after nephrectomy as a standard of care in patients with localized renal cell carcinoma at increased risk for recurrence,” says Toni K. Choueiri, MD.
Dr. Kibel discusses TRUS-guided and transperineal prostate biopsy
June 2nd 2022"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.